Deals and IPOs

Allergan to shareholders: Ignore Pershing Square


Allergan advised its stockholders to refrain from taking any action in response to Pershing Square Capital Management's proposal to replace a majority of the Botox maker's board.

A vial of Allergan’s Botox is arranged next to boxes for a photograph at a doctor's office in Manhattan Beach, Calif.
Patrick T. Fallon | Bloomberg | Getty Images

William Ackman's Pershing Square has been pushing for a special meeting of Allergan shareholders to consider the removal of six directors and the appointment of its slate of nominees.

"We believe Pershing Square's attempt to replace a majority of the Allergan Board is a further effort to support Valeant in its bid to acquire Allergan at a grossly inadequate price," Allergan said on Friday.

Allergan CEO: Restructuring & unlocking value

The company has been trying to fight off a $53 billion hostile offer from Valeant Pharmaceuticals International and activist investor William Ackman since late April.

Allergan is expected to unveil details of its plan to remain a stand-alone company when it releases second-quarter results this month.

The company has said it is considering acquisitions of its own, additional spending cuts or taking on debt to buy back shares.

Read MoreAllergan CEO to Cramer: Our anti-Valeant plan

—By Reuters